An official website of the United States government
Alzheimer’s Disease (AD) is a progressive memory disorder that causes irreversible cognitive declines, therefore early diagnosis is imperative to prevent the progression of AD. To this end, many biomarker analysis models have been presented for early AD detection. However, these models may not realize the full data potential due to their failure to integrate longitudinal (dynamic) phenotypic data with (static) genetic data. Sometimes, they may not fully utilize both labeled and unlabeled samples either. To overcome these limitations, we propose a semi-supervised enrichment learning method to learn a fixed-length vectorial representation for each participant, by which the static data record can be integrated with the dynamic data records. We have applied our new method on the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort and achieved 75% accuracy on multiclass AD progression prediction by one year in advance.
more »
« less
Neuron-level explainable AI for Alzheimer’s Disease assessment from fundus images
Alzheimer’s Disease (AD) is a progressive neurodegenerative disease and the leading cause of dementia. Early diagnosis is critical for patients to benefit from potential intervention and treatment. The retina has emerged as a plausible diagnostic site for AD detection owing to its anatomical connection with the brain. However, existing AI models for this purpose have yet to provide a rational explanation behind their decisions and have not been able to infer the stage of the disease’s progression. Along this direction, we propose a novel model-agnostic explainable-AI framework, called Granur Neuron-leel Expliner (LAVA), an interpretation prototype that probes into intermediate layers of the Convolutional Neural Network (CNN) models to directly assess the continuum of AD from the retinal imaging without the need for longitudinal or clinical evaluations. This innovative approach aims to validate retinal vasculature as a biomarker and diagnostic modality for evaluating Alzheimer’s Disease. Leveraged UK Biobank cognitive tests and vascular morphological features demonstrate significant promise and effectiveness of LAVA in identifying AD stages across the progression continuum.
more »
« less
- PAR ID:
- 10539644
- Publisher / Repository:
- Springer Nature
- Date Published:
- Journal Name:
- Scientific Reports
- Volume:
- 14
- Issue:
- 1
- ISSN:
- 2045-2322
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Event-based models (EBM) provide an important platform for modeling disease progression. This work successfully extends previous EBM approaches to work with larger sets of biomarkers while simultaneously modeling heterogeneity in disease progression trajectories. We develop and validate the s-SuStain method for scalable event-based modeling of disease progression subtypes using large numbers of features. s-SuStaIn is typically an order of magnitude faster than its predecessor (SuStaIn). Moreover, we perform a case study with s-SuStaIn using open access cross-sectional Alzheimer’s Disease Neuroimaging (ADNI) data to stage AD patients into four subtypes based on dynamic disease progression. s-SuStaIn shows that the inferred subtypes and stages predict progression to AD among MCI subjects. The subtypes show difference in AD incidence-rates and reveal clinically meaningful progression trajectories when mapped to a brain atlas.more » « less
-
Alzheimer’s disease (AD) is a serious neurodegenerative condition that affects millions of people across the world. Recently machine learning models have been used to predict the progression of AD, although they frequently do not take advantage of the longitudinal and structural components associated with multi-modal medical data. To address this, we present a new algorithm that uses the multi-block alternating direction method of multipliers to optimize a novel objective that combines multi-modal longitudinal clinical data of various modalities to simultaneously predict the cognitive scores and diagnoses of the participants in the Alzheimer’s Disease Neuroimaging Initiative cohort. Our new model is designed to leverage the structure associated with clinical data that is not incorporated into standard machine learning optimization algorithms. This new approach shows state-of-the-art predictive performance and validates a collection of brain and genetic biomarkers that have been recorded previously in AD literature.more » « less
-
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, yet its current treatments are limited to stopping disease progression. Moreover, the effectiveness of these treatments remains uncertain due to the heterogeneity of the disease. Therefore, it is essential to identify disease subtypes at a very early stage. Current data-driven approaches can be used to classify subtypes during later stages of AD or related disorders, but making predictions in the asymptomatic or prodromal stage is challenging. Furthermore, the classifications of most existing models lack explainability, and these models rely solely on a single modality for assessment, limiting the scope of their analysis. Thus, we propose a multimodal framework that utilizes early-stage indicators, including imaging, genetics, and clinical assessments, to classify AD patients into progression-specific subtypes at an early stage. In our framework, we introduce a tri-modal co-attention mechanism (Tri-COAT) to explicitly capture cross-modal feature associations. Data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (slow progressing = 177, intermediate = 302, and fast = 15) were used to train and evaluate Tri-COAT using a 10-fold stratified cross-testing approach. Our proposed model outperforms baseline models and sheds light on essential associations across multimodal features supported by known biological mechanisms. The multimodal design behind Tri-COAT allows it to achieve the highest classification area under the receiver operating characteristic curve while simultaneously providing interpretability to the model predictions through the co-attention mechanism.more » « less
-
Abstract PurposeThe objective of this study was to develop a novel AI-ensembled network based on the most important features and affected brain regions to accurately classify and exhibit the pattern of progression of the stages of Cognitive Impairment (CI). MethodsWe proposed a novel ensembled architecture, 3D ResNet-18 - RF (Random Forest), and used this network to categorize the stages of Alzheimer’s disease (AD). The residual unit (blocks of ResNet) was introduced to the 3D Convolutional Neural network (CNN) to solve the degradation problem. It was considered an innovative strategy since the combination with fine-tuning resulted in higher accuracy. This network was trained on selected features and affected brain regions. The structured magnetic resonance images (MRI) were collected from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset, and the random forest was used for determining the importance of the features and affected regions from the parcellated 170 regions of interest (ROIs) using Atlas, automated anatomical labeling 3(AAL-3). This framework classified five categories of AD and detected the progression pattern. ResultsThe proposed network showed promising results with a 66% F-1 score, 76% sensitivity, and 93.5% specificity, which outperformed the performance of conventional methods for categorizing five categories. Ventral Posterolateral and Pulvinar lateral regions were the regions most affected, indicating the progression from early MCI to AD. The five-fold validation accuracy for the developed model was 60.02%. ConclusionThe results showed that the gray matter to white matter ratio was the most significant feature, which also accurately predicted the progression pattern. The performance metrics fluctuated with different hyperparameters, but they never exceeded 0.05% of the estimated results, indicating the validity and originality of the suggested methodology.more » « less
- Free Publicly Accessible Full Text
-
Accepted Manuscript
- Journal Article:
- https://doi.org/10.1038/s41598-024-58121-8
